India, July 22 -- US President Donald Trump on Wednesday unveiled a phased tariff plan for imported generic medicines, giving manufacturers a two-year window to shift production to the United States before imposing steep import duties that could significantly affect India's pharmaceutical exports.

In a post on Truth Social, Trump said all generic drugs entering the US would continue to face zero tariffs from August 1, 2026, for two years, after which they would attract a 100% tariff from August 2028 and 200% from August 2029. The move is aimed at encouraging pharmaceutical companies to manufacture generic medicines in the US.

"Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARI...